Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply.

Aged Humans Medicare Part A Medicare Part D Pharmaceutical Preparations United States

Journal

Health affairs (Project Hope)
ISSN: 1544-5208
Titre abrégé: Health Aff (Millwood)
Pays: United States
ID NLM: 8303128

Informations de publication

Date de publication:
06 2021
Historique:
entrez: 7 6 2021
pubmed: 8 6 2021
medline: 9 7 2021
Statut: ppublish

Résumé

The proliferation of "ultra-expensive" drugs has sparked debate on their sustainability and affordability. Medicare Part D's share of annual spending on these drugs increased by 1,170 percent between 2012 and 2018, largely because the number of beneficiaries receiving them increased during this period.

Identifiants

DOI: 10.1377/hlthaff.2020.00896 PMID: 34097507
pubmed: 34097507
doi: 10.1377/hlthaff.2020.00896
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1000-1005

Auteurs

So-Yeon Kang (SY)

So-Yeon Kang (Soyeon.Kang@jhu.edu) is a PhD student in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, in Baltimore, Maryland.

Daniel Polsky (D)

Daniel Polsky is the Bloomberg Distinguished Professor of Health Economics in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, and the Johns Hopkins Carey Business School.

Jodi B Segal (JB)

Jodi B. Segal is a professor of medicine at the Johns Hopkins School of Medicine and a professor in the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health.

Gerard F Anderson (GF)

Gerard F. Anderson is a professor of health policy and management and a professor of international health at the Johns Hopkins Bloomberg School of Public Health, a professor of medicine at the Johns Hopkins School of Medicine, and director of the Johns Hopkins Center for Hospital Finance and Management.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Ultra-Expensive Drugs And Medicare Part D:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Ultra-Expensive Drugs And Medicare Part D:...
questionsmedicales.fr › Organisations et économie des soins de santé › Contrôle social formel › Législation comme sujet › Medicare part A (USA) › Ultra-Expensive Drugs And Medicare Part D:...
questionsmedicales.fr › Organisations et économie des soins de santé › Contrôle social formel › Législation comme sujet › Medicare part D (USA) › Ultra-Expensive Drugs And Medicare Part D:...
questionsmedicales.fr › Préparations pharmaceutiques › Ultra-Expensive Drugs And Medicare Part D:...
questionsmedicales.fr › Régions géographiques › Amériques › Amérique du Nord › États-Unis › Ultra-Expensive Drugs And Medicare Part D:...